We are live on ! Find out more
ECOR icon

electroCore

41 hedge funds and large institutions have $31.5M invested in electroCore in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

65% more capital inflows, than outflows

Capital inflows: $9.9M | Capital outflows: $6M

11% more funds holding

Funds holding: 37 → 41 (+4)

1.34% more ownership

Funds ownership: 13.95% → 15.29% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
16
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ECOR Hedge Fund Activity: Q1 2019 in Review

41 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in electroCore (ECOR) for Q1 2019, worth a combined $31.5M — up 23% from $25.7M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ECOR positions and 7 closed out — a net gain of 5 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.32M. The largest seller was OrbiMed, exiting entirely with an estimated $2.49M sold.

  • 41 institutional investors held electroCore (ECOR) as of Q1 2019, up from 37 in Q4 2018.
  • Funds reported $31.5M of electroCore stock for Q1 2019, up 23% quarter-over-quarter.
  • 12 funds opened new electroCore positions in Q1 2019 and 7 closed out, a net change of +5 holders.
  • The largest electroCore buyer in Q1 2019 was Vanguard Group, an estimated $3.32M added.
  • The largest electroCore seller in Q1 2019 was OrbiMed, an estimated $2.49M sold.

Based on aggregated 13F filings for Q1 2019.